Pat Garcia-Gonzalez Named Finalist for UICC’s CEO Award
The Max Foundation is proud to announce that our Chief Executive Officer Pat Garcia-Gonzalez has been named a finalist for the Union for International Cancer Control (UICC)’s CEO Award!
Innovator Jerry Radich of Fred Hutch joins The Max Foundation’s Executive Board
The Max Foundation is thrilled to welcome longtime advisor, Dr. Jerald Radich of the Fred Hutchinson Cancer Research Institute into the Executive Board. Dr. Radich has been a guiding star in our innovative work for many years helping people face cancer with dignity and hope, especially in the area of improving access to critical diagnostics in low- and middle-income countries.
Last year, The Max Foundation created a formal partnership with Fred Hutch and the Radich Lab called Spot On CML in order to increase testing for chronic myeloid leukemia (CML) patients. The Spot On CML partnership aims to test 365 patients in a year and has already helped patients in Mongolia, Nepal, Tajikistan, Timor Leste, and beyond.
Dr. Radich has an accomplished background. He is a medical oncologist who specializes in the molecular genetics of leukemia. A world-recognized expert in chronic myeloid leukemia (CML), he serves on the CML Guidelines Panels for the National Comprehensive Cancer Network and European LeukemiaNet, which synthesize the best available evidence, including findings from state-of-the-art molecular monitoring, to support optimal decision-making in the medical management of CML patients. For many years, Dr. Radich has been involved with The Max Foundation and the International CML Foundation (iCMLf), performing diagnostic and monitoring tests for CML patients in developing countries.
The Radich laboratory was one of the first to document that monitoring levels of the abnormal, CML-promoting “BCR-ABL” fusion protein can be used to detect “minimal residual disease” and predict relapse before CML cells can be detected by previously standard tests. Dr. Radich’s Lab was recognized in a New York Times article for their breakthrough work that continues to benefit patients today.
We are grateful for Dr. Radich’s ongoing support and thank him, in advance, for his continued guidance on behalf of people facing cancer worldwide.
The Max Foundation is a leading global health nonprofit organization dedicated to accelerating health equity. For 27 years, Max has pioneered practical, scalable, high-quality solutions to bring life-extending treatments and patient-centered health care to more than 100,000 people living with cancer and critical illness in low- and middle-income countries. Max believes in a world where all people can access high-impact medicines, where geography is not destiny, and where everyone can strive for health with dignity and with hope.
Related Articles
Spot On CML: Improving CML Diagnostics One Patient at a Time
February 21, 2018 · The Max Foundation and Dr. Jerry Radich of the Fred Hutchinson Cancer Research Center are partnering to help tackle the problem of access to accurate tests for chronic myeloid leukemia (CML) diagnostics in low- and middle-income countries through Spot On CML. Spot On CML is a low-cost, paper-based diagnostic testing method for CML, developed by Dr. Radich’s lab at Fred Hutch. Through a Spot On CML test, a physician spots a patient’s blood onto a paper test card and sends it to Dr. Radich’s lab for processing, where they perform accurate diagnostic testing on the samples even after weeks of transport. Once patients are diagnosed, The Max Foundation connects them with available treatments free of charge.
The Max Foundation welcomes John Menapace as CFO/VP of Administration
We are delighted to announce that John Menapace has joined the Max Foundation as CFO/VP of Administration. John brings demonstrated business leadership to his new role with a background comprising more than 20 years of experience in driving growth and profitability, across Fortune 50, Big 5, non-profit, and start-up companies. His prior roles include positions….
